Drugs / [68Ga]Ga-DOTA-TATE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06379217 | Jul 2024 → Sep 2026 overdue | prostate neuroendocrine neoplasm | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06240741 | Mar → Dec 2024 | neuroendocrine neoplasm | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT05142696 Background | Jul 2022 → Mar 2028 expected | small cell lung carcinoma | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga]Ga-DOTA-TATE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05142696 ↗ |
| Modality | Diagnostic / imaging agent | “assessed for somatostatin receptor (SSTR) expression by \[68Ga\]Ga-DOTA-TATE imaging PET/scan” NCT05142696 ↗ |
| Route | Intravenous | “Single intravenous injection of \[68Ga\]Ga-DOTA-TATE determined by body weight” NCT06240741 ↗ |